



## **AstraZeneca submission to the Post-Market Review of the Life Saving Drugs Programme**

Thank you for the invitation to provide a submission to the Post-Market Review of the Life Saving Drugs Programme (LSDP). This is an important opportunity for all stakeholders, including patients, prescribers, industry, the Department of Health and the Pharmaceutical Benefits Advisory Committee (PBAC), to work together to ensure that Australians living with rare diseases have timely and equitable access to much-needed medicines.

AstraZeneca is a global, innovation-led pharmaceutical company that is actively investing in the development of new therapies for several rare diseases, including many rare forms of cancer. We have contributed to the '*Funding Rare Disease Therapies in Australia*' report prepared by the McKell Institute, and look forward to participating in the upcoming LSDP Stakeholder Forum.